Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Genex Pharmaceutical Inc (PK:GENX)

Business Focus: Advanced Medical Equipment & Technology

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for GENX*US within the last 6 months
Loading...
See all filings within the past 6 months

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
0.00
2.82
3.21
Price to Book - most recent quarter
0.00
2.17
2.13
Price to Cash Flow per share - TTM
0.00
19.99
13.71
Price to Free Cash Flow per share - TTM
0.00
30.23
23.67
See all valuations

Business Summary

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology

Genex Pharmaceutical, Inc. (Genex) was considered a development-stage company prior to June 17, 2004. Genex was a start-up, Internet-based fulfillment company with offices in Vancouver, British Columbia, Canada. On June 8, 2004, Genex entered into a share purchase agreement with Tianjin Zhongjin Biology Development Co., Ltd. (Zhongjin). On June 17, 2004, the stock purchase made pursuant to the share purchase agreement was consummated and Zhongjin became a wholly owned subsidiary of Genex. Zhongjin engages in the business of producing and distributing Reconstituted Bone Xenograft (RBX), which is considered a medical device that accelerates bone healing. Zhongjin solely markets its medical devices to hospitals in China. Zhongjin distributes its medical devices to more than 500 hospitals in 30 provinces throughout China. Zhongjin also markets its medical devices to medical device customers in China that are not hospitals.

See business summary

 

Twitter

Search (past week) for $GENX

  • No tweets found